From: Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology
Targeted agent
Chemotherapy
N
RR
PFS (months)
OS (months)
Reference
Cetuximab
Irinotecan and FU
49
42%
8.6
16.6
Kanzler et al. [11]
Bevacizumab
Docetaxel, FU and cisplatin
44
67%
12
16.2
Kelsen et al. [12]
Irinotecan and oxaliplatin
51
60%
6
9.5
Woell et al. [13]
